Integrating biopharmaceutics risk assessment and in vivo absorption model in formulation development of BCS class I drug using the QbD approach-Reference-Cited by-同舟云学术

Integrating biopharmaceutics risk assessment and in vivo absorption model in formulation development of BCS class I drug using the QbD approach

Author:

Charoo Naseem A.¹,Cristofoletti Rodrigo²³,Kim Sun K.⁴

Affiliation:

1. Zeino Therapeutics, Khalifa Industrial Zone, Abu Dhabi, United Arab Emirates;

2. Division of Therapeutic Equivalence, Brazilian Health Surveillance Agency (ANVISA), Brasilia, Brazil;

3. Institute of Pharmaceutical Technology, Goethe University, Frankfurt am Main, Germany;

4. QbD Works LLC, Fremont, CA, USA

Publisher

Informa UK Limited

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology

Link

Reference51 articles.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Drug and formulation development processes;From Current to Future Trends in Pharmaceutical Technology;2024